Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours

International Journal of Hyperthermia

Volumn 26, Issue 5, 2010, Pages 485-498

  Yarmolenko, Pavel S ^a   Zhao, Yulin ^b   Landon, Chelsea ^b   Spasojevic, Ivan ^b   Yuan, Fan ^a   Needham, David ^c   Viglianti, Benjamin L ^d   Dewhirst, Mark W ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

Doxil; Doxorubicin; Hyperthermia; LTSL; Temperature sensitive liposome

Indexed keywords

DOXORUBICIN; LIPOSOME; LOW TEMPERATURE SENSITIVE LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PH; SINGLE DRUG DOSE; SURVIVAL RATE; TEMPERATURE SENSITIVITY; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; TOXICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERTHERMIA, INDUCED; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; TREATMENT OUTCOME;

EID: 77954393305     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656731003789284     Document Type: Article

References (61)

1. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818-1822.
2. Drummond DC, Zignani M, Leroux JC. Current status of pH-sensitive liposomes in drug delivery. Progress in Lipid Research 2000;39:409-460.
3. Jensen SS, Andresen TL, Davidsen J, Hoyrup P, Shnyder SD, Bibby MC, Gill JH, Jorgensen K. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 2004;3:1451-1458.
4. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004;10:2168-2178.
5. Hossann M, Wiggenhorn M, Schwerdt A, Wachholz K, Teichert N, Eibl H, Issels RD, Lindner LH. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 2007;1768:2491-2499.
6. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978;202:1290-1293.
7. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197-1201.
8. Poon RT, Borys N. Lyso-thermosensitive liposomal doxor-ubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009; 10:333-343.
9. Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000;6:3748-3755.
10. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia 1999;15:345-370.
11. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-3032.
12. Anyarambhatla GR, Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: A new temperature-sensitive liposome for use with mild hyperthermia. J Liposome Res 1999;9:491-506.
13. Mills JK, Needham D. Lysolipid incorporation in dipalmi- toylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 2005 Oct 15;1716(2):77-96.
14. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42:419-436.
15. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. Cancer Res 2000;60:6950-6957.
16. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004; 3:1311-1317.
17. Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia 2008; 24:475-482.
18. Hauck ML, LaRue SM, Petros WP, Poulson JM, Yu D, Spasojevic I, Pruitt AF, Klein A, Case B, Thrall DE, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006;12:4004-4010.
19. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. A phase I dose escalation tolerabilityTM study of ThermoDox (thermally sensitive liposomal doxorubicin) in combination with radiofrequency ablation (RFA) of primary and metastatic tumors of the liver; 2007. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00441376 (accessed 14 February 2010).
20. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. A phase I dose escalation study of heat activated liposome delivery of doxorubicin and radio-frequency ablation of primary and metastatic tumors of the liver; 2004. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00093444 (accessed 14 February 2010).
21. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. A phase III, randomized, double-blinded, dummy-controlled study of the efficacy and safety of ThermoDox® (thermally sensitive liposomal doxorubicin) in combination with radiofrequency ablation (RFA) compared to RFA alone in the treatment of non-resectable hepatocellular carcinoma; 2008. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00617981 (accessed 14 February 2010).
22. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. A phase I, dose escalation and pharmacokinetics study of temperature sensitive liposome encapsulated doxorubicin(ThermoDox) and hyperthermia in patients with local-regionally recurrent breast cancer; 2006. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00346229?term=ThermoDox&rank=4 (accessed 14 February 2010).
23. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986;857:123-126.
24. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem Phys Lipids 1990;53:37-46.
25. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989;49:5922-5930.
26. Wright A. Drug Loading And Release from Thermally Sensitive Liposome. Durham, NC: Duke University; 2006.
27. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magnetic Resonance in Medicine 2004;51:1153-1162.
28. DeLean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97-102.
29. Prescott DM, Charles HC, Sostman HD, Page RL, Thrall DE, Moore D, Oleson JR, Dewhirst MW. Manipulation of intra-and extracellular pH in spontaneous canine tumours by use of hyperglycaemia. Int J Hyperthermia 1993;9:745-754.
30. Allard P, Zoubeidi A, Nguyen LT, Tessier S, Tanguay S, Chevrette M, Aprikian A, Chevalier S. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol Cell Endocrinol 2000;159:63-77.
31. Aslakson CJ, Rak JW, Miller BE, Miller FR. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer 1991;47:466-472.
32. NCI/NIH Developmental Therapeutics Program DS. NCI/NIH Developmental Therapeutics Program, Discovery Series. NCI/NIH, 2010. Available from: http://dtp.nci.nih.gov/docs/misc/common-files/cell-list.html (accessed 14 February 2010).
33. Perez LA, Dombkowski D, Efird J, Preffer F, Suit HD. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: A study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Res 1995;55:392-398.
34. Rodriguez R, Ritter MA, Fowler JF, Kinsella TJ. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994;29:105-113.
35. Jones E, Alvarez Secord A, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, Clarke-Pearson D, Soper J, Dewhirst MW, Vujaskovic Z. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 2006;22:161-172.
36. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487-497.
37. Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, Felix R, Wust P. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 2005;181:35-41.
38. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®). J Liposome Res. 1994;4(1):667-687.
39. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994 Apr 15;54(8):2186-2191.
40. Dunn J. Doxorubicin-induced cardiomyopathy. J Pediatr Oncol Nurs 1994;11:152-160.
41. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994;54:4564-4568.
42. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 2000;60:4440-4445.
43. Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg 1988;18:276-283.
44. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53:285-305.
45. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 1995;55:78-82.
46. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-1674.
47. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 1992; 84:113-118.
48. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-6595.
49. Szulawska A, Czyz M. [Molecular mechanisms of anthracy-clines action]. Postepy Hig Med Dosw 2006;60:78-100.
50. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27:251-255. (Pubitemid 26129184)
51. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999;229:75-81.
52. Smith V, Raynaud F, Workman P, Kelland LR. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol Pharmacol 2001; 60:885-893.
53. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999;35:664-671.
54. El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia 2005;7:705-713.
55. Owen CS. Dependence of proton generation on aerobic or anaerobic metabolism and implications for tumour pH. Int J Hyperthermia 1996;12:495-499.
56. Wike-Hooley JL, van den Berg AP, van der Zee J, Reinhold HS. Human tumour pH and its variation. Eur J Cancer Clin Oncol 1985;21:785-791.
57. Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, Dewhirst MW. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 2000;6:2501-2505.
58. Atema A, Buurman KJ, Noteboom E, Smets LA. Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH. Int J Cancer 1993; 54:166-172.
59. Born R, Eichholtzwirth H. Effect of different physiological conditions on the action of adriamycin on Chinese hamster cells in vitro. Brit J Cancer 1981;44:241-246.
60. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, Link JM, Krohn KA. Kinetic analysis of 3-deoxy-3-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-1621.
61. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst 2007; 99:53-63.